Do Its Financials Have Any Role To Play In Driving Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Stock Up Recently?

Vcanbio Cell & Gene Engineering (SHSE:600645) has had a great run on the share market with its stock up by a significant 10% over the last month. We wonder if and what role the company's financials

Simply Wall StMay 24 19:50 ET

Zhongyuan Kyowa (600645.SH): Storage business includes neonatal cord blood hematopoietic stem cells, etc.

Gelonghui, May 14, 丨 Zhongyuan Xiehe (600645.SH) said on the investor interactive platform that the company's storage business includes neonatal umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental subpluripotent stem cells, and adult immune cells, adipose mesenchymal stem cells, and dental pulp mesenchymal stem cells. In terms of cell therapy research and development, the company's current VUM02 injection derived from umbilical cord mesenchymal stem cells has been approved for IND. Ind. indications include decompensated liver cirrhosis, idiopathic pulmonary fibrosis, slow-acute (subacute) liver failure, acute respiratory distress syndrome, and grade II to IV acute when hormone therapy fails

Gelonghui FinanceMay 14 04:04 ET

Zhongyuan Kyowa (600645.SH): The concept of synthetic biology is quite broad. Currently, the company focuses on the development of stem cell drugs

Gelonghui, May 8, 丨 Zhongyuan Xiehe (600645.SH) said on the investor interactive platform that the company's main business includes preparation and storage of cell tests in the field of “precision prevention”; research, production and marketing of in vitro diagnostic raw materials, in vitro diagnostic reagents and devices in the field of “accurate diagnosis”; research and development of clinical applications of stem cells and immune cells in the “cell therapy” field; forming a “precision medicine” industry chain. The concept of synthetic biology is quite broad. Currently, the company focuses on the research and development of stem cell drugs.

Gelonghui FinanceMay 8 04:11 ET

Zhongyuan Xiehe (600645.SH): A total of 1.65% of the company's shares have been repurchased

Gelonghui, May 6, 丨 Zhongyuan Xiehe (600645.SH) announced that as of April 30, 2024, the company had repurchased a total of 7,707,940 shares, accounting for 1.65% of the company's total share capital. The highest purchase price was 17.95 yuan/share, the lowest price was 15.11 yuan/share, and the total amount paid was 125,389,095.38 yuan (not including transaction fees).

Gelonghui FinanceMay 6 04:00 ET

Zhongyuan Concord (600645.SH) released 2023 annual results, with net profit of 106 million yuan, a year-on-year decrease of 5.78%

Zhongyuan Concord (600645.SH) released its 2023 annual report. The company achieved operating income of 15 during the reporting period...

Zhitong FinanceApr 25 10:48 ET

Zhongyuan Xiehe (600645.SH): A total of 4.7712 million shares have been repurchased

Gelonghui, April 14, 丨 Zhongyuan Xiehe (600645.SH) announced that as of April 12, 2024, the company had repurchased a total of 47712 million shares of the company through centralized bidding transactions, accounting for 1.02% of the company's total share capital, an increase of 0.28% compared with the previous disclosure. The highest purchase price was 17.50 yuan/share, the lowest price was 15.73 yuan/share, and the total amount paid was 78.21,500 yuan (not including transaction commissions and other fees).

Gelonghui FinanceApr 14 03:46 ET